Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05749289 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 20, 2024 to Dec 20, 2028 Completion date: Dec 20, 2025 to Dec 20, 2029 · Eligibility criteria expanded, about 1 word · Study description expanded, about 1 word · 1 morev3 Show 4 more changesShow less
    • Completion date: Dec 20, 2025 to Dec 20, 2029
    • Eligibility criteria expanded, about 1 word
    • Study description expanded, about 1 word
    • Study title expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Phase: Phase 1 to Phase 2/3 Enrollment target: 50 to 400 · Primary completion date: Dec 20, 2023 to Dec 20, 2024 · Completion date: Dec 20, 2024 to Dec 20, 2025v2 Show 3 more changesShow less
    • Enrollment target: 50 to 400
    • Primary completion date: Dec 20, 2023 to Dec 20, 2024
    • Completion date: Dec 20, 2024 to Dec 20, 2025
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
Trial Details
NCT Number NCT05749289
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions SSTR Positive Tumors
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov